Related Experiment Video

Updated: Mar 23, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.3K

Corticosteroids Significantly Increase Serum Cystatin C Concentration without Affecting Renal Function in Symptomatic

Jian-Long Zhai, Ning Ge, Yuzhi Zhen

    Clinical Laboratory
    |March 26, 2016
    PubMed

    Insights

    Corticosteroid treatment, like prednisone, significantly elevates serum cystatin C levels in heart failure patients. This increase is not due to impaired kidney function and should be considered during therapy.

    Area of Science:

    • Biochemistry
    • Nephrology
    • Cardiology

    Background:

    • Human cystatin C is a protein marker primarily influenced by glomerular filtration rate.
    • Non-renal factors, including medications, can significantly alter circulating cystatin C levels.
    • Symptomatic heart failure patients often have altered physiological markers.

    Purpose of the Study:

    • To investigate the impact of corticosteroid therapy on serum cystatin C concentrations.
    • To determine if corticosteroid-induced changes in cystatin C correlate with renal function.
    • To assess the clinical implications of corticosteroid use on cystatin C as a biomarker in heart failure.

    Main Methods:

    • Fifty-six patients with symptomatic heart failure received prednisone treatment.
    • Serum cystatin C and creatinine levels were measured at baseline and after two weeks of treatment.
    • Glomerular filtration rate was calculated using 24-hour urinary creatinine excretion.

    Main Results:

    • Prednisone treatment led to a significant increase in serum cystatin C (1.24 to 1.61 mg/L, p < 0.05).
    • This elevation in cystatin C was not linked to any impairment in renal function.
    • Prednisone also decreased serum creatinine and increased sodium excretion and urine flow rate, with a non-significant trend towards improved GFR.

    Conclusions:

    • Corticosteroids represent a significant non-renal factor influencing serum cystatin C levels.
    • Interpreting cystatin C values in heart failure patients undergoing corticosteroid therapy requires careful consideration of these non-renal effects.
    • The study highlights the importance of accounting for medication effects when using cystatin C as a diagnostic or monitoring tool.
    Abstract

    More Related Videos

    Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids08:02

    Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

    Published on: April 25, 2016

    10.2K
    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

    Published on: August 29, 2025

    676

    Related Concept Videos

    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    1.1K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.4K
    Heart Failure Drugs: &#946;-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    1.1K
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    1.8K
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.3K
    Heart Failure IV: Classification and Diagnostic Evaluation01:30

    Heart Failure IV: Classification and Diagnostic Evaluation

    Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
    569